INTRODUCTION AND OBJECTIVES: WST11-VTP is a promising technology in cancer treatment. Several preclinical models demonstrated higher efficacy in ablation of prostate, urothelial and kidney tumors. Likewise others ablation procedures, some normal tissue beyond the tumor's area can be affected causing some undesirable effects. Sveto et al showed the capacity of SS-20 and SS-31 peptides in reduce cells damage after ischemic kidney injury in rats. We examined combination of VTP and SS peptides on kidney tissue damage after high-dose VTP application METHODS: 28 black-6 male mice arranged in 4 different groups: VTP alone, VTP plus SS-20, VTP plus SS-31 and VTP plus SS-20 and SS-31. All mice got same high dose of VTP e 200 mW/cm / 10 0 e and retro-orbital WST11. The SS peptides dose was 2mg/Kg, gave 30 0 before VTP and daily for 4 days by subcutaneous injection. In the VTP plus SS-20/ SS-31 combination group, a single shot of SS-20 was used 30 0 before VTP and the following daily doses were just SS-31. All VTP application was performed on left kidney after surgical approach by small flank incision and renal externalization. Urea and creatinine blood exam were realized one day before VTP, 24 hrs and 72 hrs after. All mice were euthanized on day 5 after VTP and tissues of interest were collected for histology assessment by a board certificated pathologist RESULTS: After 28 mice submitted a VTP high dose treatment, just one from VTP alone group died. A reduced kidney damageanalyzed by tubular injury score-was observed in all peptides groups compare to VTP alone, but only the SS-20/SS-31 combination showed a statistical significance ( p < 0.05) . As a single agent, SS-20 seems has a better effect in kidney protection compares to SS-31. The E-Cadherin grades were lowered in all peptides treatment groups compared to VTP only (positive effect), but do not reach significance. This may be mitigated by powering the study to include more animals in each cohort. The same fact was observed in creatinine and urea results analysis. Compare to VTP alone, all peptides groups had lower creatinine and urea values 24 hrs after VTP application, but without statistical importance. Exception for SS-31 and VTP alone groups that reached statistical difference (p¼0.04) in the urea measures 24 hrs after VTP. Once again, SS-20/SS31 combination and SS-31 groups presented lowest levels of creatinine and urea on day after VTP. After 72 hrs of VTP application, creatinine and urea returned to baseline values in all groups CONCLUSIONS: The use of mitochondria-target peptides, SS-20 and SS-31, can protect the kidney against high dose VTP in a mouse model. The rationale of combine this drugs before and after VTP seems a promising approach in renal preservation and side effects prevention after VTP ablation
Source of Funding: Thompson Family Foundation

MP100-09 DOES ROUTINE BIOPSY IMPROVE DETECTION OF RESIDUAL RCC POST MICROWAVE ABLATION?
Brett Johnson*, Amy Lim, Shane Wells, Sara Best, Michael Hartung, Meghan Lubner, Timothy Ziemlewicz, J. Louis Hinshaw, Fred Lee, Wei Huang, Richard Yang, Stephen Y Nakada, E. Jason Abel, Madison, WI INTRODUCTION AND OBJECTIVES: The histologic presence of residual RCC following thermal ablation without radiographic evidence of tumor is of uncertain clinical significance. The purpose of this study is to evaluate the incidence of viable RCC in patients with no radiographic recurrence following percutaneous microwave (MW) ablation.
METHODS: Routine post-ablation biopsy was obtained approximately 9 months following ablation. Four cores were routinely sampled from the ablation bed (2 for H&E staining, 2 for NAD diaphorase testing). A pilot study included ex-vivo ablation of RCC immediately following nephrectomy to evaluate histologic effect of ablation.
RESULTS: Pilot study included 10 patients who had nephrectomy for RCC. A sample containing tumor and normal renal parenchyma was evaluated histologically following ex-vivo supratherapeutic MW ablation. Preservation of tumor histology was demonstrated in specimens evaluated after H&E processing. Fifty-six biopsy proven RCC tumors in 52 patients (37M/15F, median age: 67.5 IQR: 64 -71.3) following percutaneous MW ablation from April 2012 through May 2016 were evaluated. Median tumor diameter and nephrometry score were 2.8 cm (IQR: 2.0 -3.2) and 6.5 (IQR: 5.0 -8.0). Median Charlson Co-Morbidity Index was 2.0 (IQR: 0.75 -3.0). Clear cell histology represented 40/56 (71.4%). Median follow up was 15.3 months (IQR: 8.4 -27.0). Median time between ablation and biopsy was 9.3 months (IQR: 9.0 -10.3). Following ablation, ablation zone biopsy has no RCC present in 51/56 (91.1%) tumors while 5/56 (8.9%) had the appearance of histologically residual tumor. Positive versus negative post-ablation biopsies did not significantly differ in nephrometry score, age, tumor size, or histology (p > 0.05). In patients with residual tumor, 2 were treated with repeat ablation and 3 elected surveillance. No patients have subsequently developed radiologically identifiable kidney recurrence and one patient with negative renal ablation bed biopsy was treated surgically for recurrence outside kidney and is currently NED.
CONCLUSIONS: Histologically identifiable tumor was identified in 9% of routine biopsies in the absence of radiologic recurrence following microwave ablation. The clinical significance of preserved tissue histology is unclear as no patients have radiological recurrence in ablated renal tumors to date. 197, No. 4S, Supplement, Tuesday, May 16, 2017 THE JOURNAL OF UROLOGY â e1333 investigate the cost of pre-procedure biopsy of renal masses vs immediate cryoablation with intraoperative biopsy for patients with small renal masses who are candidates for cryotherapy. METHODS: We retrospectively identified all patients who had laparoscopic cryoablation for a renal tumor by a single surgeon at an academic center between 2004 and 2013. Pathology results from intraoperative biopsies were collected. Cost analysis was performed for two treatment algorithms. Algorithms differed in the initial step in management: CT guided biopsy vs laparoscopic cryoablation with intraoperative biopsy.
Source of Funding: None
RESULTS: There were 96 patients in the study. Pathology results from intraoperative biopsies were: Cancer: 64 (66.7%), Indeterminate: 12 (12.5%), and Benign: 20 (20.8%). Cost of laparoscopic cryoablation and hospital stay is $10,600. Cost of a CT guided biopsy is $5,400. Cost of 5 years of surveillance is $37,400. On average, the fiveyear cost to manage a patient initially with laparoscopic cryoablation is $40,200. This compares to $43,400 for CT guided biopsy as first management. In order for CT guided biopsy to be cost effective, 52% of small renal masses deemed appropriate for cryoablation would need to be benign.
CONCLUSIONS: Immediate cryoablation is slightly more cost effective than getting a pre-operative CT guided biopsy for patients considering treatment of small renal masses with laparoscopic cryoablation. The cost difference is not enough to unilaterally drive clinical decisions but shared decision making should include cost. The overwhelming cost over five years is driven by cost of surveillance imaging.
Source of Funding: none
MP100-11 PERCUTANEOUS IRREVERSIBLE ELECTROPORATION OF RENAL TUMORS: OUTCOMES AFTER MEDIAN 2 YEAR FOLLOW-UP
Igor Sorokin*, Noah Canvasser, Aaron Lay, Monica Morgan, Asim Ozayar, Jeffrey Gahan, Clayton Trimmer, Jeffrey Cadeddu, Dallas, TX INTRODUCTION AND OBJECTIVES: Percutaneous irreversible electroporation (IRE) is a novel minimally invasive technique to treat small renal tumors. IRE uses an electric field to create nano-pores within cellular membranes resulting in subsequent apoptosis. Because IRE is athermal, it offers potential advantages to radiofrequency (RFA) and cryoablation. We report on the longest followup outcomes of IRE renal tumor ablation.
METHODS: We retrospectively reviewed all IRE cases completed at our institution from April 2013-June 2016. IRE was performed using the NanoKnifeâ commercial system and 15 cm monopolar probes (AngioDynamics, NY, USA). All procedures were performed with computed tomography (CT) guidance, under general anesthesia with paralytics, and with ablation synchronized to the cardiac cycle. A minimum of three months of follow-up with a contrast-enhanced CT scan was necessary to be included in the analysis.
RESULTS: A total of 39 tumors in 38 patients underwent irreversible electroporation. Mean tumor size was 2.0 cm with a median R.E.N.A.L nephrometry score of 5. Twenty-six patients (68%) were discharged the same day of the procedure and no major (Clavien grade III or higher) intraoperative or post-operative complications occurred. Initial treatment success rate was 92%; our three failures (8%) underwent salvage radiofrequency ablation. With a median follow-up of 25.2 months, two-year local recurrence-free survival was 76% for patients with biopsy confirmed renal cell carcinoma, 84% with biopsy confirmed or a history of renal cell carcinoma, and 90% for the intent-to-treat cohort (figure 1).
CONCLUSIONS: Percutaneous irreversible electroporation has suboptimal short-term local disease control results compared to thermal ablation in this series of small, low complexity tumors. Larger series and longer follow-up is still needed to determine the durability of this modality for renal cell carcinoma.
Source of Funding: none
MP100-12 SHOULD PATHOLOGIC DIAGNOSIS BE OBTAINED PRIOR TO RENAL MASS ABLATION?
Amy H. Lim*, Shane Wells, Matthew Grimes, Tyler Wittmann, Sara Best, James Louis Hinshaw, Fred T. Lee, Meghan Lubner, Timothy Ziemiewicz, Stephen Y. Nakada, E. Jason Abel, Madison, WI INTRODUCTION AND OBJECTIVES: Pathologic diagnosis of cancer in renal masses allows for optimal patient selection before treatment and appropriate follow-up after thermal ablation. However, biopsy is still often performed at the same time as ablation and pathologic findings are either non-diagnostic or benign in 7-45% of tumors in large ablation series. The objective of this study was to compare findings for renal mass biopsies obtained prior to treatment (priorbx) to biopsies obtained on the same day as ablation (samedaybx).
METHODS: An institutional database identified consecutive patients with renal masses treated with thermal ablation from 2001-2015. Patients treated without biopsy (37) were excluded. Radiologic tumor and patient data were reviewed. Fischer's exact or chi-square tests were used to evaluate differences between groups, non-diagnostic biopsy rate and the rate of ablation for benign tumors.
RESULTS: A total of 280 renal tumors were treated with ablation including 197 (70.4%) with priorbx and 83 (29.6%) with samedaybx. There was nodifference in patient or tumor characteristics between samedaybx and priorbx groups (table). Priorbx patients had longer skin-to-tumor distance median 10.5 vs. 8cm, p¼0.0001. Non-diagnostic biopsy findings were significantly more common in patients with samedaybx compared to priorbx, 14.5% vs. 1.5%, p<0.001. Ablation of oncocytoma was also more common in patients with samedaybx compared to priorbx, 15.7% vs. 3.0%, p<0.001. RCC diagnosis was obtained in only 69.9% of tumors with samedaybx compared to 95.4% of tumors with priorbx, p<0.001.
CONCLUSIONS: Pre-ablation biopsy is associated with a decreased rate of treatment for benign and unidentified renal tumors and better diagnostic yield than same day renal biopsy. This approach has clear benefits to patients considering thermal ablation of small renal masses.
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